These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 33151791)

  • 1. Patient initiation and maintenance of GLP-1 RAs for treatment of obesity: a narrative review and practical considerations for primary care providers.
    Fitch A; Ingersoll AB
    Postgrad Med; 2021 Apr; 133(3):310-319. PubMed ID: 33151791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigational glucagon-like peptide-1 agonists for the treatment of obesity.
    Tomlinson B; Hu M; Zhang Y; Chan P; Liu ZM
    Expert Opin Investig Drugs; 2016 Oct; 25(10):1167-79. PubMed ID: 27563838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obstetrician-Gynecologists' Strategies for Patient Initiation and Maintenance of Antiobesity Treatment with Glucagon-Like Peptide-1 Receptor Agonists.
    Gill L; Mackey S
    J Womens Health (Larchmt); 2021 Jul; 30(7):1016-1027. PubMed ID: 33626287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient initiation and maintenance of GLP-1 RAs for treatment of obesity.
    Patel D; Smith A
    Expert Rev Clin Pharmacol; 2021 Oct; 14(10):1193-1204. PubMed ID: 34231442
    [No Abstract]   [Full Text] [Related]  

  • 5. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome.
    Tzotzas T; Karras SN; Katsiki N
    Curr Vasc Pharmacol; 2017; 15(3):218-229. PubMed ID: 28003008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liraglutide: A New Option for the Treatment of Obesity.
    Nuffer WA; Trujillo JM
    Pharmacotherapy; 2015 Oct; 35(10):926-34. PubMed ID: 26497479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liraglutide: A Glucagon-Like Peptide-1 Agonist for Chronic Weight Management.
    Manigault KR; Thurston MM
    Consult Pharm; 2016 Dec; 31(12):685-697. PubMed ID: 28074747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of glucagon-like peptide 1 receptor agonists in management of obesity.
    Isaacs D; Prasad-Reddy L; Srivastava SB
    Am J Health Syst Pharm; 2016 Oct; 73(19):1493-507. PubMed ID: 27521241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL.
    Torekov SS
    Cardiovasc Res; 2018 Aug; 114(10):e70-e71. PubMed ID: 30052921
    [No Abstract]   [Full Text] [Related]  

  • 10. Exposure-response analyses of liraglutide 3.0 mg for weight management.
    Wilding JP; Overgaard RV; Jacobsen LV; Jensen CB; le Roux CW
    Diabetes Obes Metab; 2016 May; 18(5):491-9. PubMed ID: 26833744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GLP-1R agonists for the treatment of obesity: a patent review (2015-present).
    Liu C; Zou Y; Qian H
    Expert Opin Ther Pat; 2020 Oct; 30(10):781-794. PubMed ID: 32799587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiobesity efficacy of GLP-1 receptor agonist liraglutide is associated with peripheral tissue-specific modulation of lipid metabolic regulators.
    Decara J; Arrabal S; Beiroa D; Rivera P; Vargas A; Serrano A; Pavón FJ; Ballesteros J; Dieguez C; Nogueiras R; Rodríguez de Fonseca F; Suárez J
    Biofactors; 2016 Nov; 42(6):600-611. PubMed ID: 27213962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists.
    Christensen RM; Juhl CR; Torekov SS
    Drug Saf; 2019 Aug; 42(8):957-971. PubMed ID: 30972641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity.
    Burcelin R; Gourdy P
    Obes Rev; 2017 Jan; 18(1):86-98. PubMed ID: 27636208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of GLP-1 Receptor Agonists in Pediatric Obesity: Benefits, Risks, and Approaches to Patient Selection.
    Page LC; Freemark M
    Curr Obes Rep; 2020 Dec; 9(4):391-401. PubMed ID: 33085056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
    Nørregaard PK; Deryabina MA; Tofteng Shelton P; Fog JU; Daugaard JR; Eriksson PO; Larsen LF; Jessen L
    Diabetes Obes Metab; 2018 Jan; 20(1):60-68. PubMed ID: 28598027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials.
    O'Neil PM; Aroda VR; Astrup A; Kushner R; Lau DCW; Wadden TA; Brett J; Cancino AP; Wilding JPH;
    Diabetes Obes Metab; 2017 Nov; 19(11):1529-1536. PubMed ID: 28386912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evaluation of liraglutide including its efficacy and safety for the treatment of obesity.
    Lin CH; Shao L; Zhang YM; Tu YJ; Zhang Y; Tomlinson B; Chan P; Liu Z
    Expert Opin Pharmacother; 2020 Feb; 21(3):275-285. PubMed ID: 31790314
    [No Abstract]   [Full Text] [Related]  

  • 19. Liraglutide: a review of its use in the management of obesity.
    Scott LJ
    Drugs; 2015 May; 75(8):899-910. PubMed ID: 25985864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. liraglutide (SAXENDA⁰) and obesit. Still no satisfactory weight loss drugs.
    Prescrire Int; 2016 Jan; 25(167):5-8. PubMed ID: 26942248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.